An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Status:
Completed
Trial end date:
2013-12-06
Target enrollment:
Participant gender:
Summary
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth
hormone (GH), generally caused by a GH-secreting pituitary adenoma. The study assessed the
long-term safety and efficacy of pasireotide in participants with acromegaly.